![Nesya Goris](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Nesya Goris
Direktor/Vorstandsmitglied bei THERAVET SA
Aktive Positionen von Nesya Goris
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
THERAVET SA | Direktor/Vorstandsmitglied | 20.12.2021 | - |
Independent Dir/Board Member | 20.12.2021 | - | |
ViroVet NV
![]() ViroVet NV Pharmaceuticals: MajorHealth Technology ViroVet NV is a Belgian company that focuses on the discovery, licensing, and development of biopharmaceutical products for livestock. The company is based in Leuven, Belgium. ViroVet was founded by Erwin Blomsma, Stefaan Wera, and Nesya Goris, with Erwin Blomsma serving as the CEO since incorporation. | Gründer | - | - |
Corporate Officer/Principal | - | - | |
Flanders Vaccine | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Nesya Goris
Ehemalige bekannte Positionen von Nesya Goris
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
AnimAb BV
![]() AnimAb BV BiotechnologyHealth Technology AnimAb BV is a Belgian company that focuses on improving animal performance through its antibody-based approach that targets intestinal pathogens. AnimAb is based in Ghent, Belgium. The company helps protect piglets during their most fragile post-weaning stage. AnimAb integrates cutting-edge research, animal science, and biotechnology for product breakthroughs in animal health, cost-efficiencies, and sustainability. The company's technology prevents intestinal bacterial colonization thanks to the direct integration with animal feed. The company's cross-disciplinary science teams developed a new antibody technology designed for oral ingestion based on a scalable, cost-effective microbial production process. The company was founded in 2020 by Eric Cox, Henri de Greve, Ann Depicker, and Nico Callewaert. Alain Wille has been the CEO of the company since 2020. | General Counsel | - | - |
Aratana Therapeutics NV
![]() Aratana Therapeutics NV Pharmaceuticals: OtherHealth Technology Aratana Therapeutics NV engages in the development and marketing of veterinary medicine. It offers Entyce, nocita, and Galliprant. The company was founded on December 20, 2007 and is headquartered in Leuven, Belgium. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2008 | - |
Ausbildung von Nesya Goris
Katholieke Universiteit Leuven | Graduate Degree |
Ghent University | Doctorate Degree |
Statistik
International
Belgien | 8 |
Operativ
Director/Board Member | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 3 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
THERAVET SA | Commercial Services |
Private Unternehmen | 4 |
---|---|
Aratana Therapeutics NV
![]() Aratana Therapeutics NV Pharmaceuticals: OtherHealth Technology Aratana Therapeutics NV engages in the development and marketing of veterinary medicine. It offers Entyce, nocita, and Galliprant. The company was founded on December 20, 2007 and is headquartered in Leuven, Belgium. | Health Technology |
ViroVet NV
![]() ViroVet NV Pharmaceuticals: MajorHealth Technology ViroVet NV is a Belgian company that focuses on the discovery, licensing, and development of biopharmaceutical products for livestock. The company is based in Leuven, Belgium. ViroVet was founded by Erwin Blomsma, Stefaan Wera, and Nesya Goris, with Erwin Blomsma serving as the CEO since incorporation. | Health Technology |
AnimAb BV
![]() AnimAb BV BiotechnologyHealth Technology AnimAb BV is a Belgian company that focuses on improving animal performance through its antibody-based approach that targets intestinal pathogens. AnimAb is based in Ghent, Belgium. The company helps protect piglets during their most fragile post-weaning stage. AnimAb integrates cutting-edge research, animal science, and biotechnology for product breakthroughs in animal health, cost-efficiencies, and sustainability. The company's technology prevents intestinal bacterial colonization thanks to the direct integration with animal feed. The company's cross-disciplinary science teams developed a new antibody technology designed for oral ingestion based on a scalable, cost-effective microbial production process. The company was founded in 2020 by Eric Cox, Henri de Greve, Ann Depicker, and Nico Callewaert. Alain Wille has been the CEO of the company since 2020. | Health Technology |
Flanders Vaccine |
- Börse
- Insiders
- Nesya Goris
- Erfahrung